StreetAlpha.app
Home › Stocks › JANX

Janux Therapeutics, Inc. (JANX)

Healthcare
Members
LATEST PRICE

Janux Therapeutics develops immunotherapy drugs that direct the immune system's T cells to attack tumors and autoimmune disease. JANX reports earnings on Thu, Nov 5, 2026.

Prices, price targets and earnings estimates for JANX are shown to AI Starter and AI Pro members. Ratings, flow and news are open to everyone.See plans
AI Auto Pilots
Is JANX in one of our four AI portfolios? Sign in free to see
See how it works→ Details ↓

Earnings

Earnings calendar →
Next report
Nov 5
2026 · Time not announced
Consensus EPS forecast
Members
EPS and revenue estimates
Year-ago EPS
Members
Same quarter last year
Options-implied move
Members
Move priced in by options
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated JANX in the past 90 days, not enough for a consensus
Average 12-month target
Price targets for JANXThe average, highest and lowest analyst targets and the target chart are shown to AI Starter and AI Pro members.See plans
Latest rating changes
Wolfe ResearchUpgrade
Aug 24Buy
GuggenheimMaintained
Aug 7Buy
Truist SecuritiesAssumed coverage
Jun 25Buy
BarclaysDowngrade
Apr 20Sell
UBSDowngrade
Apr 15Hold
DateFirmActionRatingPrice target
Aug 24Wolfe ResearchUpgradeBuy
Aug 7GuggenheimMaintainedBuy
Jun 25Truist SecuritiesAssumed coverageBuy
Apr 20BarclaysDowngradeSell
Apr 15UBSDowngradeHold
Loading…

Whale Options Flow

90D

No whale options trades in JANX in the last 90 days.

Loading…

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether JANX is in one of them and how their past JANX trades turned out.

See how it works→ View all auto pilots→
JANX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered JANX in an article yet. Here's the latest on the wider market.

macronewsFriday, October 30, 2026
Binance and Polymarket Hacks Test Crypto's Plumbing, Not Yet Macro
Binance paused withdrawals after a suspected theft of roughly $6 billion, while Polymarket halted trading for an hour after a vendor breach.
Jean Westart · 3 min read
macronewsMonday, October 26, 2026
S&P 500 Sits 2.5% Below Its Record Ahead of the Fed and Big Tech
The S&P 500 slipped 0.47% to 7,623.68, 2.5% below its record, as the Fed meets October 28 and Alphabet, Microsoft and Amazon report.
Marie Crown · 3 min read
macronewsMonday, October 26, 2026
Hightower's Stephanie Link Tells Investors to Add on Volatility
Hightower's Stephanie Link told CNBC's Squawk Box that investors should use market volatility to add to portfolios as earnings season unfolds.
Adam Landser · 2 min read

About Janux Therapeutics

Janux Therapeutics is a biopharmaceutical company based in San Diego, California. It develops immunotherapy drugs that direct the body's T cells to attack tumors, and it is also developing treatments for autoimmune diseases. Its lead candidates are in clinical trials for prostate cancer and other solid tumors. The company's drug candidates are aimed at cancer patients and people living with autoimmune conditions.

Headquarters
San Diego, CA
Summary based on the company’s 2026 annual report (10-K) ↗